John Costello / Inquirer
At the Wachovia Center, Broad Street Atrium, Comcast workers get ready for "SportsNite." The cable giant is still striving to dominate the nation’s Internet and telephone service.
Page: 9 of 10 View All
Market cap and total return leaders
The region’s powerhouses and big producers are sparkling with projects for the future. Most of the companies’ stock-and-dividend returns were down.
Incyte is developing biotech drugs hoping to treat conditions like human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. Among its experimental compounds are potential treatments for myelofibrosis, rheumatoid arthritis, psoriasis, Type 2 diabetes, breast cancer and multiple sclerosis.
The Chatter: Launched in 1991 to develop gene-mapping technology, and once commanding $140 a share, Incyte now pursues small-molecule drugs itself, but hasn't topped $20 in years. Its yearlong stock rise got close, but then turned south recently after an experimental product got a negative review.
30 S. 17th St., Philadelphia
215-972-0420
Founded 1977
President/CEO: Michael J. McKelvey
NASDAQ: ERES
Market cap: $810 million *
Stock-div return one year: 58 percent **
Working on the back end of drug development, eResearch helps pharmaceutical, biotech and medical-device companies collect and interpret cardiac safety and clinical data. Its products include the EXPeRT Cardiac Safety data-management system and EXPeRT Portal that gives clinical trial researchers and staff real-time access to progress reports. It also provides study initiation, project management, technology- and regulatory-review services.
The Chatter: The worse things got on drug safety in recent years, the better it got for companies like eResearch, which does the testing. Wall Street cheered McKelvey's appointment a year ago and kept buying.
